Does bisoprolol improve the 3-year patient-oriented composite endpoint compared to carvedilol in patients with acute myocardial infarction and reduced LVEF undergoing PCI?
Bisoprolol and carvedilol demonstrated comparable 3-year cardiovascular outcomes in patients with acute myocardial infarction and reduced LVEF undergoing PCI, suggesting both are suitable options for secondary prevention.
Among patients with AMI and reduced LVEF undergoing PCI, bisoprolol and carvedilol showed comparable 3-year cardiovascular outcomes. Both agents appear to be suitable options for secondary prevention in this high-risk population.
Jeong et al. (Wed,) studied this question.